What are the CHADS2 score risk levels and annual stroke rates?

CHADS2 annual stroke rates: 0 = 1.9%, 1 = 2.8%, 2 = 4.0%, 3 = 5.9%, 4 = 8.5%, 5 = 12.5%, 6 = 18.2% per year (from Gage et al., JAMA 2001 cohort). These rates represent untreated patients. Oral anticoagulation reduces stroke risk by ~64-70% relative to no treatment in AF. These absolute risk estimates guide the risk-benefit discussion for anticoagulation.

What does HAS-BLED score mean alongside CHADS2?

HAS-BLED estimates bleeding risk during anticoagulation: H = uncontrolled hypertension (>160 mmHg SBP), A = abnormal renal (creatinine >2.3) or liver function (cirrhosis), S = stroke history, B = bleeding history or predisposition, L = labile INR (TTR 65), D = drugs (NSAIDs/antiplatelets) or alcohol. Score ≥3 = high bleeding risk. HAS-BLED should not be used to withhold anticoagulation but to identify and address modifiable bleeding risks (blood pressure control, NSAID discontinuation) in patients who need anticoagulation.

Can CHADS2 be used for atrial flutter?

Yes. Atrial flutter carries the same thromboembolic risk as atrial fibrillation. AF and AFL frequently coexist in the same patient, and flutter itself is associated with atrial structural changes that promote thrombus formation. ACC/AHA guidelines recommend applying the same anticoagulation approach (using CHA2DS2-VASc, with NOACs preferred) to atrial flutter as to atrial fibrillation.

What is atrial fibrillation stroke prevention?

AF stroke prevention is primarily achieved through oral anticoagulation (NOAC or warfarin). Mechanism: AF causes disorganized atrial electrical activity leading to stagnant blood flow in the left atrial appendage, promoting thrombus formation. If a thrombus embolizes, it typically causes cardioembolic stroke — often more severe than atherothrombotic stroke. Anticoagulation (not antiplatelet therapy — aspirin is substantially inferior) reduces cardioembolic stroke by ~64-70% in AF. Left atrial appendage occlusion (WATCHMAN device) is an alternative for patients who cannot take anticoagulation long-term.

Is CHADS2 still referenced in clinical practice?

CHADS2 is still referenced in: (1) historical literature and clinical trials published before 2010-2012; (2) some institutional protocols that have not fully updated to CHA2DS2-VASc; (3) educational settings where CHADS2 is taught as the foundational AF score; (4) resource-limited environments. However, ACC/AHA 2019 and ESC 2020 guidelines have fully replaced CHADS2 with CHA2DS2-VASc as the recommended clinical tool. Current clinical practice should use CHA2DS2-VASc.

What is the role of left atrial appendage occlusion in AF stroke prevention?

Left atrial appendage occlusion (LAAO) with the WATCHMAN device is FDA-approved for non-valvular AF patients who have an appropriate rationale for seeking a non-pharmacological alternative to long-term anticoagulation (e.g., prior major bleeding, patient preference). PROTECT-AF and PREVAIL trials showed non-inferiority to warfarin for stroke prevention. LAAO is not superior to NOACs and is generally reserved for patients with contraindications to long-term anticoagulation. CHA2DS2-VASc ≥2 is typically required for LAAO consideration.

What is the history and significance of the CHADS2 score?

CHADS2 was developed by Gage et al. (JAMA 2001) from analysis of 1,733 Medicare patients with AF enrolled in the National Registry of Atrial Fibrillation (NRAF). It was a major advance over previous AF risk stratification approaches (high/medium/low risk categories) by providing a quantitative, reproducible score with specific annual stroke rates. CHADS2 standardized AF anticoagulation decision-making and was adopted by ACC/AHA and ESC guidelines from 2006-2012. CHA2DS2-VASc (Lip et al., Chest 2010) was subsequently developed to improve risk discrimination and has fully replaced CHADS2 in current guidelines.

Online Medical Tools — CHADS2 Score

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Cardiology

CHADS2 Score

CHADS2 is a historical atrial fibrillation stroke risk model that assigns points for congestive heart failure, hypertension, age >=75, diabetes, and prior stroke/TIA (2 points). It remains useful for educational context and quick baseline risk framing, although modern practice commonly uses CHA2DS2-VASc for finer stratification.

Formula: CHADS2 = CHF (1) + HTN (1) + Age >=75 (1) + Diabetes (1) + Prior Stroke/TIA (2).

Congestive heart failure

Hypertension

Age >= 75 years

Diabetes mellitus

Prior stroke or TIA

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Score 5 clinical risk factors for AF-related stroke

Assign points for each present risk factor: Congestive Heart Failure or LVEF <40% (1 point), Hypertension — diagnosed or on treatment (1 point), Age ≥75 years (1 point), Diabetes mellitus (1 point), prior Stroke or TIA (2 points). The maximum total score is 6 points. All variables are obtained from the clinical history without requiring laboratory results.

Sum points to get CHADS2 score (0-6)

Sum all applicable points: CHADS2 0 = 1.9% annual stroke risk; CHADS2 1 = 2.8%; CHADS2 2 = 4.0%; CHADS2 3 = 5.9%; CHADS2 4 = 8.5%; CHADS2 5 = 12.5%; CHADS2 6 = 18.2%. Prior stroke or TIA is the highest weighted item (2 points), reflecting the particularly high recurrent stroke risk in patients with prior cerebrovascular events.

Apply to anticoagulation decision — using CHA2DS2-VASc for modern practice

NOTE: CHA2DS2-VASc is now universally preferred over CHADS2 for anticoagulation decisions per ACC/AHA 2019 and ESC 2020 AF guidelines. Use CHA2DS2-VASc for clinical management. CHADS2 is most useful for educational reference, reviewing historical clinical trial data, or resource-limited settings. Anticoagulation is recommended for CHA2DS2-VASc ≥2 in men and ≥3 in women (NOAC preferred over warfarin).

Who Uses the CHADS2 Score

Historical Reference in AF Stroke Risk

Cardiologists, electrophysiologists, general physicians

CHADS2 was the standard AF stroke risk tool from 2001-2010 before CHA2DS2-VASc was validated. Understanding CHADS2 is essential for interpreting older clinical trial data, historical cohort studies, and pre-2010 treatment guidelines that reference CHADS2 for anticoagulation decisions.

Teaching and Medical Education

Medical students, resident physicians, educators

CHADS2 is commonly taught as the foundational AF stroke risk score because its five straightforward risk factors illustrate the core concept of AF stroke risk stratification. It demonstrates the rationale for anticoagulation in AF and provides a clinical framework that students can build upon when learning CHA2DS2-VASc.

Comparing CHADS2 to CHA2DS2-VASc

Clinicians transitioning to CHA2DS2-VASc, clinical pharmacists

Calculating both CHADS2 and CHA2DS2-VASc for the same patient illustrates how CHA2DS2-VASc identifies additional intermediate-risk patients (age 65-74, vascular disease, female sex) who benefit from anticoagulation but would have been missed by CHADS2 alone. This comparison demonstrates the clinical advantage of the newer score.

Patient Education on AF Stroke Risk Factors

All clinicians, patient educators

The five CHADS2 factors — CHF, hypertension, age, diabetes, stroke history — are the core modifiable and non-modifiable AF stroke risk factors. Discussing these with patients in the context of CHADS2 (or CHA2DS2-VASc) helps patients understand why anticoagulation is recommended and motivates risk factor control.

Resource-Limited Settings Without Full CHA2DS2-VASc Data

Clinicians in resource-limited settings

In clinical settings where detailed vascular history (coronary disease, PAD, aortic plaque) required for CHA2DS2-VASc may be difficult to ascertain, CHADS2 provides a practical 5-factor approximation. However, CHA2DS2-VASc should be used whenever possible.

Pro Tips

CHA2DS2-VASc is universally preferred over CHADS2 in current practice

Both ACC/AHA 2019 AF Guidelines (January et al., JACC 2019) and ESC 2020 AF Guidelines (Hindricks et al., Eur Heart J 2021) replaced CHADS2 with CHA2DS2-VASc as the recommended stroke risk stratification tool. Use CHA2DS2-VASc for all clinical anticoagulation decisions. CHADS2 is now primarily used for historical reference and education.

CHADS2 misses intermediate-risk patients who benefit from anticoagulation

CHADS2 scores 0-1 include a heterogeneous group ranging from truly low-risk to intermediate-risk patients. CHA2DS2-VASc better identifies intermediate-risk patients by adding age 65-74 (1 pt), vascular disease (1 pt), and female sex (1 pt). These additions capture patients who CHADS2 misses but who have meaningful stroke risk. CHA2DS2-VASc score 0 in males is the only truly low-risk category not requiring anticoagulation.

CHADS2 score 0 does NOT mean anticoagulation is unnecessary

A CHADS2 score of 0 does not mean the patient is truly low risk. A patient aged 65-74 with vascular disease and female sex would score CHADS2 = 0 but CHA2DS2-VASc = 3 — indicating meaningful stroke risk that warrants anticoagulation. Always use CHA2DS2-VASc to identify truly low-risk patients (score 0 in males, 1 in females = anticoagulation not recommended).

Prior stroke or TIA carries double weight — and is the strongest predictor

Prior stroke or TIA is the most powerful single predictor of recurrent stroke in AF, reflecting both the established cardioembolic mechanism and the vulnerable cerebrovascular state. It contributes 2 points to CHADS2 and 2 points to CHA2DS2-VASc. Patients with prior stroke/TIA have approximately 10-12% annual recurrent stroke risk without anticoagulation — anticoagulation is strongly indicated regardless of other factors.

NOAC (direct oral anticoagulants) are preferred over warfarin for non-valvular AF

Apixaban, rivaroxaban, dabigatran, and edoxaban are preferred over warfarin for non-valvular AF anticoagulation per ACC/AHA and ESC guidelines. NOACs have equivalent or superior efficacy, lower intracranial hemorrhage risk, and simpler management (no INR monitoring). Warfarin remains preferred for AF with mitral stenosis or mechanical heart valves, where NOACs are not approved.

Atrial flutter carries identical thromboembolic risk to atrial fibrillation

Atrial flutter has the same thromboembolic risk as AF and requires the same anticoagulation approach guided by CHADS2 or CHA2DS2-VASc score. Many patients with flutter also have AF, and flutter itself promotes atrial structural remodeling. Do not withhold anticoagulation from AFL patients with high stroke risk scores on the basis that the rhythm is 'not AF.'

Successful cardioversion or rhythm control does NOT eliminate anticoagulation indication

Patients who undergo cardioversion or catheter ablation and maintain sinus rhythm still require continued anticoagulation if their CHA2DS2-VASc score warrants it. Even successfully rhythm-controlled patients may have brief asymptomatic AF recurrences detected by implantable monitors. Long-term anticoagulation should be based on CHA2DS2-VASc score, not presumed freedom from AF.

Always assess HAS-BLED score alongside CHADS2/CHA2DS2-VASc

HAS-BLED score assesses bleeding risk in AF anticoagulation: H (hypertension), A (abnormal renal/liver function), S (stroke history), B (bleeding history or predisposition), L (labile INR), E (elderly, age >65), D (drugs/alcohol). HAS-BLED ≥3 indicates high bleeding risk — address modifiable bleeding risk factors (blood pressure control, NSAIDs discontinuation) rather than withholding anticoagulation, which remains net beneficial in most high-CHA2DS2-VASc patients.

Both valvular and non-valvular AF require anticoagulation — warfarin for valvular

CHADS2 and CHA2DS2-VASc were developed and validated for non-valvular AF. Patients with AF and rheumatic mitral stenosis or mechanical heart valves require anticoagulation (warfarin, not NOACs) regardless of CHADS2/CHA2DS2-VASc score — the indication is absolute. NOACs are specifically not approved for AF with moderate-severe mitral stenosis or mechanical valves.

Common Questions About Your Results

No. ACC/AHA 2019 and ESC 2020 AF guidelines both replaced CHADS2 with CHA2DS2-VASc as the recommended clinical tool. CHA2DS2-VASc provides better risk discrimination, identifies intermediate-risk patients missed by CHADS2, and has been prospectively validated in larger AF populations. Use CHA2DS2-VASc for all modern AF anticoagulation decisions. CHADS2 is appropriate for educational context and interpreting historical data.

Yes, in most cases. Successful cardioversion or catheter ablation does not eliminate the need for long-term anticoagulation if the CHA2DS2-VASc score indicates elevated stroke risk. Even patients who appear to be in stable sinus rhythm may have brief, asymptomatic AF recurrences undetected without long-term monitoring. Current guidelines recommend continuing anticoagulation based on CHA2DS2-VASc score, not on the assumption of permanent sinus rhythm maintenance.

For CHADS2, congestive heart failure includes: clinically diagnosed heart failure regardless of EF, or LVEF <40% on echocardiogram even without overt HF symptoms. Some guidelines also include patients with recent HF decompensation requiring hospitalization. Asymptomatic LV systolic dysfunction (LVEF <40% without symptoms) qualifies as the CHF criterion. The HFpEF component is less clearly defined — most use any clinical heart failure diagnosis.

Fall risk is a common reason cited for withholding anticoagulation, but evidence suggests this concern is often overweighted. A patient would need to fall approximately 295 times per year for the bleeding risk from falls to exceed the stroke prevention benefit of anticoagulation at CHA2DS2-VASc ≥2. Modifiable fall risk factors should be addressed (physical therapy, home safety, medication review), and anticoagulation should generally not be withheld based on fall risk alone in patients with elevated stroke risk scores.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher CHADS2 scores reflect increasing annual thromboembolic stroke risk in non-valvular atrial fibrillation.

When to Use This Tool

Use this score for quick educational AF stroke risk framing or when reviewing historical literature that reports CHADS2 cohorts.

Limitations

CHADS2 is less granular than CHA2DS2-VASc and may under-classify risk in some patients. It should not replace full modern risk-benefit assessment.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Cardiology

CHA₂DS₂-VASc Score

Calculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.

Open Cardiology

HAS-BLED Score

Calculate the HAS-BLED score to assess bleeding risk in patients on anticoagulation therapy. Balance stroke prevention against bleeding risk.

Open Cardiology

TIMI NSTEMI

Calculate the TIMI risk score for NSTEMI and unstable angina to predict 14-day adverse cardiac events.

Open Cardiology

ASCVD Risk Calculator

Estimate 10-year ASCVD risk using the 2013 ACC/AHA Pooled Cohort Equations, with the risk thresholds from the 2018 AHA/ACC cholesterol guideline.

Open

Frequently Asked Questions

The CHADS2 score is a clinical prediction tool developed by Gage et al. (JAMA 2001) to estimate annual stroke risk in patients with non-valvular atrial fibrillation (AF). It scores five risk factors: Congestive Heart Failure (1 pt), Hypertension (1 pt), Age ≥75 (1 pt), Diabetes mellitus (1 pt), and prior Stroke/TIA (2 pts). The maximum score is 6. Higher scores indicate greater annual stroke risk without anticoagulation.

CHADS2 (5 factors, 0-6 scale) was replaced by CHA2DS2-VASc (9 factors, 0-9 scale) in current guidelines. CHA2DS2-VASc adds three risk modifiers: age 65-74 (1 pt), vascular disease — prior MI, PAD, or aortic plaque (1 pt), and female sex (1 pt). These additions better identify intermediate-risk patients with meaningful stroke risk who scored 0-1 on CHADS2. CHA2DS2-VASc score 0 in males or 1 in females is truly low risk where anticoagulation can be omitted.

ACC/AHA 2019 and ESC 2020 guidelines: OAC is recommended for CHA2DS2-VASc ≥2 in men and ≥3 in women. OAC should be considered for CHA2DS2-VASc 1 in men (net clinical benefit likely). OAC is not indicated for CHA2DS2-VASc 0 in men or 1 in women (if the only point is female sex). NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF. Warfarin is reserved for mitral stenosis or mechanical heart valves.

Four NOACs are approved for non-valvular AF stroke prevention: Apixaban (Eliquis) 5 mg twice daily (ARISTOTLE trial, superior to warfarin for stroke reduction and bleeding); Rivaroxaban (Xarelto) 20 mg daily with evening meal (ROCKET-AF); Dabigatran (Pradaxa) 150 mg twice daily (RE-LY trial); Edoxaban (Savaysa/Lixiana) 60 mg daily (ENGAGE AF-TIMI 48). All are preferred over warfarin per current guidelines. Apixaban generally has the most favorable bleeding profile.

CHADS2 score 0: 1.9% annual stroke risk — in modern practice, CHA2DS2-VASc should be calculated; if CHA2DS2-VASc is also 0 (in male) or 1 (in female, only for sex), anticoagulation is not indicated. CHADS2 score 1: 2.8% annual stroke risk — significant, but CHA2DS2-VASc may be higher. A patient aged 65-70 with hypertension scores CHADS2 = 1 but CHA2DS2-VASc = 3 (age 65-74 adds 1, hypertension adds 1) — anticoagulation is clearly indicated by CHA2DS2-VASc.

Online Medical Tools — CHADS2 Score

CHADS2 Score

How It Works

Score 5 clinical risk factors for AF-related stroke

Sum points to get CHADS2 score (0-6)

Apply to anticoagulation decision — using CHA2DS2-VASc for modern practice

Who Uses the CHADS2 Score

Historical Reference in AF Stroke Risk

Teaching and Medical Education

Comparing CHADS2 to CHA2DS2-VASc

Patient Education on AF Stroke Risk Factors

Resource-Limited Settings Without Full CHA2DS2-VASc Data

Pro Tips

CHA2DS2-VASc is universally preferred over CHADS2 in current practice

CHADS2 misses intermediate-risk patients who benefit from anticoagulation

CHADS2 score 0 does NOT mean anticoagulation is unnecessary

Prior stroke or TIA carries double weight — and is the strongest predictor

NOAC (direct oral anticoagulants) are preferred over warfarin for non-valvular AF

Atrial flutter carries identical thromboembolic risk to atrial fibrillation

Successful cardioversion or rhythm control does NOT eliminate anticoagulation indication

Always assess HAS-BLED score alongside CHADS2/CHA2DS2-VASc

Both valvular and non-valvular AF require anticoagulation — warfarin for valvular

Common Questions About Your Results

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

CHA₂DS₂-VASc Score

HAS-BLED Score

TIMI NSTEMI

ASCVD Risk Calculator

Further Reading

A Complete Guide to Cardiology: Risk Scores, Heart Failure, and Cardiovascular Disease Management

Frequently Asked Questions